Medical School · Year 2 · Microbiology · includes a discussion video

Lecture 16: Antimicrobial Agents

Unit 2.8: Microbiology

Learning Objectives

By the end of this lecture, students will be able to:

1. Describe the general principles of antimicrobial therapy
2. Explain cell wall synthesis inhibitors (beta-lactams, glycopeptides)
3. Describe protein synthesis inhibitors
4. Explain nucleic acid synthesis inhibitors
5. Describe antimicrobial resistance mechanisms
6. Explain principles of antimicrobial stewardship

Lecture Outline

I. Antimicrobial Principles

The foundation of antimicrobial therapy rests on understanding key pharmacodynamic concepts that govern how antibiotics interact with bacteria. Bactericidal agents directly kill bacteria, causing a reduction in the number of viable organisms; examples include beta-lactams, aminoglycosides, fluoroquinolones, vancomycin, and metronidazole. Bacteriostatic agents inhibit bacterial growth without directly killing, relying on host immune defenses to eliminate the organisms; examples include tetracyclines, macrolides (generally), chloramphenicol, clindamycin, and linezolid. The minimum inhibitory concentration (MIC) represents the lowest concentration of an antibiotic that prevents visible bacterial growth after overnight incubation, serving as the primary measure of antimicrobial activity. The minimum bactericidal concentration (MBC) is the lowest concentration that kills 99.9 percent of the original inoculum; a bactericidal agent typically has an MBC within 2-4 fold of the MIC, while a large MBC-to-MIC ratio suggests bacteriostatic activity.

The spectrum of antimicrobial activity describes the range of organisms against which an antibiotic is effective. Narrow-spectrum agents target a limited group of organisms, such as penicillin G's activity primarily against gram-positive cocci, Treponema pallidum, and some anaerobes. Broad-spectrum agents cover multiple classes of organisms including both gram-positive and gram-negative bacteria; while therapeutically useful, broad-spectrum use promotes resistance selection and disrupts normal microbiota. Extended-spectrum specifically refers to agents with activity against Pseudomonas aeruginosa, an intrinsically resistant gram-negative pathogen of significant clinical importance. The distinction between empiric therapy (initiated before organism identification based on the most likely pathogens) and directed therapy (tailored to culture results and susceptibility testing) is fundamental to antibiotic management.

Pharmacokinetic and pharmacodynamic (PK/PD) principles guide optimal dosing strategies. Time-dependent killing characterizes beta-lactams and vancomycin, where efficacy correlates with the duration that free drug concentrations exceed the MIC (fT>MIC); frequent dosing or continuous infusion maximizes efficacy for these agents. Concentration-dependent killing characterizes aminoglycosides and fluoroquinolones, where efficacy correlates with peak concentration relative to MIC (Cmax/MIC) or the area under the concentration-time curve relative to MIC (AUC/MIC); once-daily dosing of aminoglycosides exploits this principle while allowing drug-free intervals to reduce toxicity. The post-antibiotic effect (PAE) describes continued suppression of bacterial growth after drug concentrations fall below MIC, particularly pronounced for aminoglycosides and fluoroquinolones against gram-negative bacteria.

Tissue penetration varies substantially among antimicrobials and must be considered when selecting therapy for different infection sites. Cerebrospinal fluid penetration is essential for treating meningitis; many antibiotics that are effective systemically achieve inadequate CSF concentrations. Beta-lactams generally penetrate CSF poorly except when meninges are inflamed; third-generation cephalosporins (ceftriaxone, cefotaxime) achieve therapeutic CSF levels for meningitis. Fluoroquinolones and metronidazole penetrate CSF well, while aminoglycosides and vancomycin penetrate poorly. Bone penetration is important for osteomyelitis; fluoroquinolones and linezolid achieve good bone concentrations. Prostate penetration (relevant for prostatitis) is limited for many agents; fluoroquinolones and trimethoprim-sulfamethoxazole penetrate well. Abscess penetration is often limited by the acidic, hypoxic environment; surgical drainage is usually required as an adjunct to antimicrobial therapy.

<image> Panel A: Illustration comparing bactericidal and bacteriostatic mechanisms, showing bacterial killing curve with bactericidal agent achieving rapid decline in colony counts versus bacteriostatic agent maintaining stable numbers, with reliance on immune clearance depicted.

Panel B: Graph demonstrating MIC determination using broth microdilution method, with serial dilutions of antibiotic and growth indicated by turbidity, identifying the MIC as the lowest concentration with no visible growth.

Panel C: Pharmacokinetic/pharmacodynamic diagram contrasting time-dependent killing (beta-lactams, showing fT>MIC importance) with concentration-dependent killing (aminoglycosides, showing Cmax/MIC ratio), including dosing strategies for each.

Panel D: Body diagram showing tissue penetration of major antibiotic classes at different sites (CSF, bone, prostate, abscess), with color coding indicating good, moderate, or poor penetration for each drug class. </image>

II. Beta-Lactam Antibiotics

Beta-lactam antibiotics constitute the most widely prescribed class of antimicrobials, sharing a common four-membered beta-lactam ring essential for activity. The mechanism of action involves binding to penicillin-binding proteins (PBPs), which are bacterial enzymes (transpeptidases, carboxypeptidases) responsible for cross-linking peptidoglycan chains during cell wall synthesis. By inhibiting transpeptidase activity, beta-lactams prevent the final step of peptidoglycan synthesis, resulting in a weakened cell wall that cannot withstand osmotic pressure. Autolysins, normally involved in cell wall remodeling, continue their activity unopposed, leading to cell lysis and death. Because beta-lactams target cell wall synthesis, they are bactericidal but only active against actively growing bacteria; they have no activity against organisms without cell walls (Mycoplasma) or those within intact cells.

The penicillins represent the original beta-lactam class and include several subgroups with distinct spectra. Natural penicillins (penicillin G, penicillin V) retain excellent activity against streptococci, Treponema pallidum (syphilis), and some anaerobes but are susceptible to staphylococcal penicillinase (beta-lactamase). Antistaphylococcal penicillins (nafcillin, oxacillin, dicloxacillin) have a modified side chain that resists staphylococcal penicillinase, making them the drugs of choice for methicillin-susceptible Staphylococcus aureus (MSSA) infections; they have no activity against methicillin-resistant S. aureus (MRSA), which possesses an altered PBP2a encoded by the mecA gene. Aminopenicillins (ampicillin, amoxicillin) have extended gram-negative coverage including Haemophilus influenzae, Escherichia coli (many strains), and Listeria monocytogenes, plus enterococcal activity, but are susceptible to many beta-lactamases. Antipseudomonal penicillins (piperacillin, ticarcillin) provide Pseudomonas coverage. The addition of beta-lactamase inhibitors (clavulanate, sulbactam, tazobactam) extends activity to beta-lactamase-producing organisms, making combinations like amoxicillin-clavulanate and piperacillin-tazobactam broadly useful.

Cephalosporins are organized into generations reflecting their spectrum of activity, with successive generations generally having broader gram-negative coverage but reduced gram-positive activity. First-generation cephalosporins (cefazolin, cephalexin) have excellent gram-positive coverage (staphylococci, streptococci) and limited gram-negative activity; cefazolin is the preferred agent for surgical prophylaxis and MSSA infections when penicillin allergy history is favorable. Second-generation cephalosporins (cefuroxime, cefoxitin) have improved gram-negative coverage; cefoxitin notably has anaerobic activity including Bacteroides fragilis. Third-generation cephalosporins (ceftriaxone, ceftazidime, cefotaxime) have excellent gram-negative coverage and CSF penetration, making ceftriaxone first-line for community-acquired meningitis; ceftazidime uniquely has Pseudomonas activity but weaker gram-positive coverage. Fourth-generation cefepime combines gram-positive activity approaching first-generation drugs with gram-negative coverage including Pseudomonas. Fifth-generation ceftaroline is unique in having activity against MRSA (through binding to PBP2a) while maintaining broad gram-negative coverage, though it lacks Pseudomonas activity.

Carbapenems (meropenem, imipenem, ertapenem, doripenem) have the broadest spectrum of any beta-lactams, with activity against most gram-positive, gram-negative, and anaerobic bacteria. They are resistant to hydrolysis by most beta-lactamases including extended-spectrum beta-lactamases (ESBLs) and AmpC beta-lactamases, making them drugs of choice for serious infections caused by ESBL-producing organisms. Imipenem requires co-administration with cilastatin to prevent renal metabolism by dehydropeptidase. Ertapenem lacks Pseudomonas and Enterococcus activity but has convenient once-daily dosing. All carbapenems are susceptible to carbapenemases, enzymes that represent a growing threat. Monobactams (aztreonam) have the unique property of gram-negative-only activity with no cross-reactivity with penicillins in allergic patients, as the monobactam ring structure differs sufficiently from penicillins and cephalosporins. Aztreonam is safe in patients with IgE-mediated penicillin allergy.

<image> Panel A: Chemical structure diagram showing the beta-lactam ring common to all beta-lactam antibiotics, with modifications depicting penicillins, cephalosporins, carbapenems, and monobactams, highlighting the structural features that determine spectrum and beta-lactamase stability.

Panel B: Mechanism of action illustration showing beta-lactam binding to penicillin-binding proteins (PBPs) on the bacterial cell wall, inhibition of transpeptidase cross-linking of peptidoglycan, and subsequent cell lysis due to osmotic instability.

Panel C: Pyramid diagram showing the evolution of cephalosporin generations from first to fifth, with gram-positive coverage decreasing and gram-negative coverage increasing through successive generations, with fifth-generation adding MRSA activity.

Panel D: Spectrum comparison chart showing the coverage of major beta-lactam classes against key pathogens (MSSA, MRSA, Enterococcus, Pseudomonas, anaerobes, ESBL producers), with checkmarks indicating coverage. </image>

III. Other Cell Wall Agents

Vancomycin is a glycopeptide antibiotic that inhibits cell wall synthesis through a mechanism distinct from beta-lactams. The drug binds to the D-alanyl-D-alanine terminus of peptidoglycan precursors (lipid II), preventing both transglycosylation (chain elongation) and transpeptidation (cross-linking). This large molecule cannot penetrate the outer membrane of gram-negative bacteria, restricting its spectrum to gram-positive organisms. Vancomycin is a cornerstone of therapy for serious MRSA infections including bacteremia, endocarditis, pneumonia, and bone and joint infections. Oral vancomycin is used for Clostridioides difficile infection, as it is not absorbed and achieves high intraluminal concentrations. Intravenous vancomycin requires therapeutic drug monitoring with trough levels or, increasingly, area under the curve (AUC) guided dosing to optimize efficacy and minimize nephrotoxicity; target AUC/MIC ratios of 400-600 are recommended for serious MRSA infections.

Vancomycin toxicity includes nephrotoxicity (particularly with concurrent nephrotoxins or prolonged therapy), ototoxicity, and the characteristic "red man syndrome," an infusion-related histamine release reaction causing flushing, pruritus, and hypotension that is preventable by slowing the infusion rate. Vancomycin-resistant enterococci (VRE) possess vanA or vanB gene clusters that modify the peptidoglycan precursor from D-Ala-D-Ala to D-Ala-D-Lactate, eliminating vancomycin binding. VRE, particularly Enterococcus faecium, has become an important nosocomial pathogen. Vancomycin-intermediate S. aureus (VISA) exhibits thickened cell walls that trap vancomycin, reducing its effectiveness, while rare vancomycin-resistant S. aureus (VRSA) strains have acquired the vanA gene from enterococci.

Newer lipoglycopeptides address some limitations of vancomycin. Dalbavancin and oritavancin have extremely long half-lives enabling weekly or even single-dose therapy, valuable for patients requiring prolonged treatment but unable to receive daily infusions. Telavancin adds membrane-disrupting activity to the glycopeptide mechanism, enhancing bactericidal activity. These agents maintain activity against VISA but not VRSA. Daptomycin is a lipopeptide antibiotic with a novel mechanism: it inserts into the bacterial cell membrane, causing depolarization, potassium efflux, and rapid cell death without cell lysis. Daptomycin has potent activity against gram-positive bacteria including MRSA and VRE. It is approved for bacteremia and right-sided endocarditis; importantly, it is inactivated by pulmonary surfactant and cannot be used for pneumonia. Daptomycin-resistant S. aureus can emerge during therapy, often in the setting of VISA. Monitoring for myopathy (elevated creatine phosphokinase) is required.

Fosfomycin inhibits an early step in peptidoglycan synthesis by blocking MurA, the enzyme that catalyzes the first committed step. It has broad-spectrum activity including many ESBL-producing Enterobacteriaceae and is available as single-dose oral therapy for uncomplicated urinary tract infections. The drug achieves high urinary concentrations despite low serum levels, making it unsuitable for systemic infections. Its unique mechanism and lack of cross-resistance with other antibiotics make it valuable for multidrug-resistant urinary pathogens. Other cell wall-active agents include bacitracin (topical only, inhibits lipid carrier recycling) and cycloserine (used for tuberculosis, inhibits D-alanine synthesis).

<image> Panel A: Molecular mechanism diagram comparing vancomycin binding to D-Ala-D-Ala terminus of peptidoglycan precursor (blocking transglycosylation and transpeptidation) with the resistance mechanism in VRE showing the altered D-Ala-D-Lac terminus that prevents vancomycin binding.

Panel B: Illustration of daptomycin mechanism showing insertion of the lipopeptide into the bacterial cell membrane, formation of pores, membrane depolarization with potassium efflux, and rapid bacterial death without lysis.

Panel C: Pharmacokinetic profile comparison of vancomycin (requiring daily dosing with trough monitoring) versus long-acting lipoglycopeptides (dalbavancin, oritavancin) showing extended half-lives enabling weekly or single-dose therapy.

Panel D: Clinical decision flowchart for selecting gram-positive cell wall agents based on organism (MSSA, MRSA, VRE) and infection site (bacteremia, pneumonia, UTI), including drug selection and monitoring requirements. </image>

IV. Protein Synthesis Inhibitors - 30S Ribosome

Aminoglycosides are bactericidal antibiotics that target the 30S ribosomal subunit, binding to the 16S ribosomal RNA and causing misreading of the genetic code during translation. This misreading results in production of aberrant proteins that are incorporated into the cell membrane, increasing permeability and enhancing further drug uptake in a concentration-dependent manner. Aminoglycoside uptake requires oxygen-dependent active transport, explaining their lack of activity against anaerobic bacteria. The class includes gentamicin, tobramycin, amikacin, streptomycin, and neomycin (topical only). These agents have excellent activity against aerobic gram-negative bacteria including Pseudomonas aeruginosa. They exhibit concentration-dependent killing with a prolonged post-antibiotic effect, supporting once-daily (extended-interval) dosing that maximizes peak concentrations while allowing drug-free intervals to reduce accumulation in renal tubular cells and the inner ear.

The primary clinical role of aminoglycosides is in serious gram-negative infections, often in combination with beta-lactams for synergistic killing. Synergy with cell wall-active agents (beta-lactams, vancomycin) occurs because disruption of the cell wall enhances aminoglycoside penetration; this synergy is particularly important for enterococcal endocarditis, where aminoglycosides combined with ampicillin or vancomycin achieve bactericidal activity that neither agent achieves alone. Tobramycin is preferred for Pseudomonas and is available as inhaled formulation for cystic fibrosis patients. Streptomycin and gentamicin are used for plague, tularemia, and brucellosis. Aminoglycoside toxicity includes nephrotoxicity (typically reversible acute tubular injury) and ototoxicity (irreversible damage to cochlear and vestibular hair cells). Risk factors include prolonged therapy, high trough levels, concurrent nephrotoxins, and pre-existing renal impairment. Monitoring of drug levels guides dosing adjustments.

Tetracyclines bind reversibly to the 30S ribosomal subunit, blocking attachment of aminoacyl-tRNA to the A site and preventing peptide elongation. They are bacteriostatic with broad-spectrum activity including atypical pathogens (Mycoplasma, Chlamydia, Rickettsia), spirochetes (Borrelia, Leptospira), and some protozoa. Doxycycline is the most commonly used agent, with excellent oral bioavailability and twice-daily dosing. Tetracyclines are first-line for rickettsial diseases (Rocky Mountain spotted fever, ehrlichiosis), Lyme disease, chlamydial infections, and acne. They are alternatives for community-acquired pneumonia and MRSA skin infections. Toxicities include photosensitivity (enhanced sunburn), tooth discoloration and enamel hypoplasia in children (contraindicated under age 8 and in pregnancy), esophageal ulceration (take with water, remain upright), and gastrointestinal upset.

Glycylcyclines, represented by tigecycline, are modified tetracyclines that overcome common tetracycline resistance mechanisms (ribosomal protection proteins and efflux pumps). Tigecycline has an exceptionally broad spectrum including MRSA, VRE, ESBL-producing Enterobacteriaceae, and anaerobes. It is available only intravenously and is approved for complicated skin and soft tissue infections, complicated intra-abdominal infections, and community-acquired pneumonia. An important limitation is an FDA black box warning regarding increased mortality in clinical trials, particularly for ventilator-associated pneumonia and bacteremia; tigecycline should not be used for bloodstream infections, as serum concentrations are low due to extensive tissue distribution. Common adverse effects include nausea and vomiting.

<image> Panel A: Illustration of the bacterial 30S ribosomal subunit showing aminoglycoside binding to 16S rRNA, causing codon misreading and incorporation of incorrect amino acids into nascent proteins, with downstream effects on membrane integrity.

Panel B: Once-daily aminoglycoside dosing graph showing the concentration-dependent killing principle with high peak concentrations achieving maximal bacterial killing, followed by drug-free interval to minimize accumulation and toxicity, with post-antibiotic effect maintaining suppression.

Panel C: Mechanism diagram of tetracycline binding to the 30S subunit blocking aminoacyl-tRNA access to the ribosomal A site, with comparison to glycylcycline (tigecycline) binding that evades resistance mechanisms.

Panel D: Clinical indications chart for 30S inhibitors showing specific uses: aminoglycosides (gram-negative sepsis, enterococcal synergy), doxycycline (rickettsial diseases, Lyme, atypicals), and tigecycline (multidrug-resistant infections, with black box warning notation). </image>

V. Protein Synthesis Inhibitors - 50S Ribosome

Macrolides bind to the 23S ribosomal RNA of the 50S subunit, blocking the peptide exit tunnel and preventing translocation of peptidyl-tRNA from the A site to the P site. This results in premature release of incomplete peptide chains and bacteriostatic activity against most organisms, though bactericidal activity occurs against some species at high concentrations. The class includes erythromycin (prototype, limited by gastrointestinal side effects), clarithromycin, and azithromycin. Azithromycin has become the most widely prescribed antibiotic, owing to its excellent tissue penetration (particularly respiratory tract), prolonged tissue half-life allowing short treatment courses (often 3-5 days), and once-daily dosing. The spectrum includes gram-positive cocci (streptococci, with emerging resistance), Haemophilus influenzae, atypical respiratory pathogens (Mycoplasma, Chlamydia, Legionella), and Mycobacterium avium complex. Azithromycin is first-line for community-acquired pneumonia (often combined with beta-lactam), chlamydial genital infections (single-dose), and MAC prophylaxis in AIDS.

Macrolide toxicity includes QT prolongation with potential for torsades de pointes (particularly with erythromycin and clarithromycin), gastrointestinal symptoms (erythromycin is also a motilin agonist), and hepatotoxicity. Erythromycin and clarithromycin are potent CYP3A4 inhibitors, causing numerous drug interactions; azithromycin has minimal CYP450 activity. Macrolide resistance has increased substantially, particularly in Streptococcus pneumoniae and Streptococcus pyogenes, driven by ribosomal methylation (erm genes conferring cross-resistance to macrolides, lincosamides, and streptogramin B) and efflux (mef genes).

Clindamycin binds to the 23S rRNA of the 50S subunit at a site overlapping with macrolides, blocking peptide bond formation. It has excellent activity against gram-positive cocci (including most community-acquired MRSA strains) and anaerobes (particularly important for aspiration pneumonia and intra-abdominal infections), but no activity against aerobic gram-negatives or Enterococcus. Clindamycin suppresses toxin production in streptococcal and staphylococcal toxic shock syndromes and necrotizing fasciitis, providing a rationale for its inclusion in these severe infections. The major limitation is its strong association with Clostridioides difficile infection, occurring through disruption of colonic microbiota. The D-test is a laboratory method to detect inducible clindamycin resistance in staphylococci that appear erythromycin-resistant but clindamycin-susceptible; if positive, clindamycin may fail clinically despite appearing susceptible on routine testing.

Linezolid is an oxazolidinone antibiotic with a unique mechanism: it binds to the 23S rRNA of the 50S subunit and prevents formation of the initiation complex by blocking the binding of aminoacyl-tRNA to the A site. This mechanism results in bacteriostatic activity against most organisms. Linezolid has excellent activity against gram-positive bacteria including MRSA and VRE (one of few oral options for VRE infections) and is used for pneumonia (including nosocomial MRSA pneumonia, where it may have advantages over vancomycin due to lung penetration), skin infections, and bacteremia. Near-complete oral bioavailability allows IV-to-oral conversion without dose adjustment. Toxicities include myelosuppression (particularly thrombocytopenia) with prolonged therapy exceeding two weeks, peripheral neuropathy with extended use, and serotonin syndrome when combined with serotonergic drugs (linezolid is a weak monoamine oxidase inhibitor). Tedizolid is a newer oxazolidinone with once-daily dosing and potentially reduced toxicity.

<image> Panel A: Diagram of the bacterial 50S ribosomal subunit showing the binding sites of macrolides, clindamycin, and linezolid on the 23S rRNA, with their respective mechanisms: macrolides blocking the peptide exit tunnel, clindamycin inhibiting peptide bond formation, and linezolid preventing initiation complex formation.

Panel B: Comparison of macrolide pharmacokinetics showing erythromycin (short half-life, multiple daily doses, CYP3A4 inhibitor), clarithromycin (twice daily, moderate CYP effect), and azithromycin (once daily, extensive tissue concentration, minimal CYP effect).

Panel C: Clinical scenario flowchart for selecting 50S inhibitors: macrolides for atypical pneumonia, clindamycin for anaerobic infections and toxin suppression (with C. difficile risk notation), linezolid for VRE and MRSA pneumonia.

Panel D: Illustration of the D-test for inducible clindamycin resistance showing the flattening of the clindamycin zone adjacent to erythromycin disk (D-shape), indicating that clindamycin resistance may be induced and the drug should not be used. </image>

VI. Nucleic Acid Synthesis Inhibitors

Fluoroquinolones inhibit bacterial DNA synthesis by targeting two essential enzymes: DNA gyrase (topoisomerase II), primarily in gram-negative bacteria, and topoisomerase IV, primarily in gram-positive bacteria. These enzymes are required for DNA supercoiling, replication, and repair. By trapping the enzyme-DNA complex after strand cleavage but before religation, fluoroquinolones cause double-strand DNA breaks that are lethal to the cell. This mechanism produces rapid, concentration-dependent bactericidal activity. The class includes ciprofloxacin (best Pseudomonas activity), levofloxacin (respiratory fluoroquinolone with improved gram-positive coverage), and moxifloxacin (best gram-positive and anaerobic coverage, but no Pseudomonas activity). The spectrum encompasses gram-negative bacteria, atypical respiratory pathogens, and variable gram-positive activity depending on the specific agent.

Fluoroquinolone clinical uses include urinary tract infections (ciprofloxacin, levofloxacin), respiratory tract infections including community-acquired pneumonia (levofloxacin, moxifloxacin), bone and joint infections (excellent bone penetration), intra-abdominal infections (moxifloxacin), and Pseudomonas infections (ciprofloxacin). Toxicity concerns have led to FDA black box warnings and restricted indications. Tendon rupture (particularly Achilles tendon) occurs with increased risk in elderly patients, those receiving corticosteroids, and transplant recipients; quinolones should be avoided when safer alternatives exist. QT prolongation and cardiac arrhythmias (most significant with moxifloxacin), central nervous system effects (seizures, confusion, particularly in elderly), aortic aneurysm and dissection, and hypoglycemia are additional concerns. Resistance has increased substantially due to overuse, limiting the utility of this once-versatile class.

Metronidazole is a nitroimidazole prodrug that requires reduction of its nitro group to generate cytotoxic intermediates. This reduction occurs only under anaerobic conditions, explaining its selectivity for anaerobic bacteria and certain protozoa (Giardia, Entamoeba, Trichomonas). The reduced intermediates cause DNA strand breakage and destabilization of the DNA helix. Metronidazole is a cornerstone for treating anaerobic infections including Bacteroides fragilis, intra-abdominal infections (combined with agents covering aerobes), bacterial vaginosis, and as first-line oral therapy for C. difficile infection in non-severe cases. It has no activity against aerobic or microaerophilic bacteria. Toxicity includes a disulfiram-like reaction with alcohol (patients must avoid alcohol during and for 72 hours after treatment), metallic taste, and peripheral neuropathy with prolonged use.

Trimethoprim-sulfamethoxazole (TMP-SMX) combines two agents that act sequentially in the folate synthesis pathway, essential for nucleotide production. Sulfamethoxazole inhibits dihydropteroate synthase (competing with para-aminobenzoic acid), while trimethoprim inhibits dihydrofolate reductase. Individually bacteriostatic, the combination is synergistic and often bactericidal. The spectrum includes gram-positive organisms (including community-acquired MRSA), many Enterobacteriaceae, Pneumocystis jirovecii, Stenotrophomonas maltophilia, and Nocardia. Clinical uses include uncomplicated UTIs (though resistance limits empiric use in many areas), MRSA skin and soft tissue infections, PCP treatment and prophylaxis, and infections due to Stenotrophomonas and Nocardia. Toxicity includes hypersensitivity reactions (sulfa allergy, Stevens-Johnson syndrome), hyperkalemia (trimethoprim blocks ENaC), bone marrow suppression, and photosensitivity. TMP-SMX is avoided in late pregnancy (kernicterus risk) and in patients with G6PD deficiency receiving high doses.

<image> Panel A: Mechanism diagram showing fluoroquinolone binding to DNA gyrase-DNA complex, trapping the enzyme after strand cleavage and preventing religation, resulting in double-strand breaks and cell death, with comparison of gyrase (gram-negative target) and topoisomerase IV (gram-positive target).

Panel B: Spectrum comparison chart for fluoroquinolones showing ciprofloxacin (Pseudomonas focus), levofloxacin (respiratory), and moxifloxacin (anaerobes, gram-positive), with toxicity warnings including tendon rupture, QT prolongation, and aortic effects.

Panel C: Illustration of metronidazole mechanism showing reduction of the nitro group under anaerobic conditions generating cytotoxic intermediates that damage DNA, with clinical applications for anaerobes and protozoa noted.

Panel D: Folate synthesis pathway diagram showing the sequential inhibition by sulfamethoxazole (dihydropteroate synthase) and trimethoprim (dihydrofolate reductase), demonstrating the synergistic mechanism of TMP-SMX. </image>

VII. Antimicrobial Resistance

Antimicrobial resistance is among the greatest threats to global health, with over 2.8 million antibiotic-resistant infections occurring annually in the United States alone. Resistance mechanisms can be categorized into several fundamental types. Enzymatic inactivation involves the production of enzymes that modify or destroy the antibiotic before it reaches its target; beta-lactamases are the most clinically important example, with the spectrum ranging from narrow-spectrum penicillinases to broad-spectrum carbapenemases. Target modification alters the structure of the antibiotic's binding site, reducing affinity; examples include altered penicillin-binding proteins (mecA in MRSA), ribosomal methylation (erm genes conferring macrolide-lincosamide-streptogramin B resistance), and modified DNA gyrase (fluoroquinolone resistance). Efflux pumps actively expel antibiotics from the bacterial cell before they reach effective concentrations; these pumps may be specific (tetracycline efflux) or multidrug (contributing to intrinsic Pseudomonas resistance). Decreased permeability through altered porins limits antibiotic entry into gram-negative bacteria; loss of OprD porin contributes to carbapenem resistance in Pseudomonas.

Beta-lactamases represent the most important resistance mechanism for the most-prescribed antibiotic class. The Ambler classification divides beta-lactamases into four molecular classes: Class A includes TEM and SHV penicillinases, ESBLs (CTX-M, SHV variants) that hydrolyze third-generation cephalosporins, and KPC carbapenemases; Class B includes metallo-beta-lactamases (NDM, VIM, IMP) that require zinc for activity and hydrolyze all beta-lactams except aztreonam; Class C includes AmpC enzymes that are chromosomally encoded in many Enterobacteriaceae and can be induced by certain beta-lactams; Class D includes OXA-type enzymes, some of which are carbapenemases. Extended-spectrum beta-lactamases (ESBLs) confer resistance to penicillins, cephalosporins, and aztreonam, but are inhibited by clavulanate and susceptible to carbapenems. Carbapenemases (KPC, NDM, OXA-48) represent the most concerning threat, as they hydrolyze nearly all beta-lactams and often occur in organisms with multiple other resistance mechanisms.

Multidrug-resistant organisms of particular clinical concern have been designated priority pathogens by WHO. Methicillin-resistant Staphylococcus aureus (MRSA) carries the mecA gene encoding PBP2a, an altered penicillin-binding protein with low affinity for all beta-lactams except ceftaroline. MRSA causes both community-acquired and healthcare-associated infections with limited treatment options. Vancomycin-resistant Enterococcus (VRE), primarily E. faecium, carries vanA or vanB genes and is an important cause of healthcare-associated infections, particularly in immunocompromised hosts. ESBL-producing Enterobacteriaceae (Escherichia coli, Klebsiella pneumoniae) are increasingly common in both healthcare and community settings. Carbapenem-resistant Enterobacteriaceae (CRE) represent the most urgent threat due to extremely limited treatment options (often only colistin, tigecycline, or ceftazidime-avibactam). Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii cause serious healthcare-associated infections with intrinsic and acquired resistance to multiple classes.

Laboratory detection of resistance relies on both phenotypic and genotypic methods. Phenotypic testing includes disk diffusion (measuring zone of inhibition around antibiotic disk), broth microdilution (determining MIC), and gradient diffusion (E-test strips). Results are interpreted using Clinical and Laboratory Standards Institute (CLSI) or European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints to classify isolates as susceptible, intermediate, or resistant. Special phenotypic tests include the D-test for inducible clindamycin resistance, modified carbapenem inactivation method (mCIM) for carbapenemase detection, and ESBL confirmatory testing. Genotypic testing using PCR or whole-genome sequencing can rapidly identify specific resistance genes (mecA, vanA, KPC, NDM) and is increasingly used for both clinical decision-making and epidemiologic surveillance.

<image> Panel A: Schematic diagram showing the four major mechanisms of antimicrobial resistance: enzymatic inactivation (beta-lactamase destroying beta-lactam), target modification (altered PBP preventing binding), efflux pump (antibiotic expelled from cell), and decreased permeability (lost porin blocking entry).

Panel B: Beta-lactamase classification pyramid showing the hierarchy from narrow-spectrum penicillinases through ESBLs to carbapenemases (KPC, NDM, OXA-48), with the spectrum of beta-lactams hydrolyzed by each group.

Panel C: Timeline showing the emergence of major resistant pathogens: MRSA (1960s), VRE (1980s), ESBL (1990s), CRE (2000s), with mortality rates and treatment challenges indicated.

Panel D: Laboratory plate images demonstrating resistance detection methods: disk diffusion with zones of inhibition, E-test strip showing MIC, modified Hodge test for carbapenemase, and D-test for inducible clindamycin resistance. </image>

VIII. Selecting Antimicrobial Therapy

The selection of appropriate antimicrobial therapy requires integration of multiple clinical factors including the likely pathogen, infection site, host factors, and local resistance patterns. Empiric therapy, initiated before culture results are available, should cover the most likely pathogens based on the clinical syndrome while avoiding unnecessary broad-spectrum coverage when narrower options are appropriate. Knowledge of local antibiograms (cumulative susceptibility data from the institution or community) guides empiric choices, as resistance patterns vary substantially by geography and healthcare setting. Patient factors influencing antibiotic selection include drug allergies, renal and hepatic function (affecting drug clearance and dosing), pregnancy status (avoiding teratogenic agents), immune status (more aggressive therapy for immunocompromised patients), and ability to take oral medications.

Empiric therapy recommendations follow evidence-based guidelines tailored to specific infection syndromes. For community-acquired pneumonia in outpatients without comorbidities, amoxicillin or doxycycline is recommended; those with comorbidities receive amoxicillin-clavulanate plus a macrolide or a respiratory fluoroquinolone. Inpatient CAP typically requires ceftriaxone plus azithromycin or a respiratory fluoroquinolone alone. Uncomplicated urinary tract infections are treated with nitrofurantoin, TMP-SMX (if local resistance is below 20 percent), or fosfomycin. Uncomplicated skin and soft tissue infections are treated with cephalexin or dicloxacillin for purulent infections likely due to MSSA, or doxycycline or TMP-SMX for presumed MRSA. Intra-abdominal infections require coverage of enteric gram-negatives and anaerobes, typically with piperacillin-tazobactam or ceftriaxone plus metronidazole. Bacterial meningitis empiric therapy combines ceftriaxone plus vancomycin (to cover penicillin-resistant pneumococci), with ampicillin added for Listeria coverage in patients over 50, immunocompromised, or with alcoholism.

De-escalation and directed therapy are essential components of appropriate antimicrobial management. Once culture results and susceptibilities are available (typically 48-72 hours), empiric broad-spectrum therapy should be narrowed to the most targeted effective agent. This de-escalation reduces selective pressure for resistance, minimizes disruption of normal microbiota, decreases drug costs, and reduces potential toxicity. Directed therapy selection considers the antibiotic's spectrum (choosing the narrowest effective agent), site of infection (ensuring adequate penetration), patient factors (adjusting for organ dysfunction), and practical considerations (oral versus intravenous, dosing frequency, cost). Intravenous-to-oral conversion should occur once patients meet criteria: clinical improvement, afebrile, functioning gastrointestinal tract, and availability of an oral agent with appropriate bioavailability and spectrum.

Duration of antimicrobial therapy has been a focus of recent research, with evidence supporting shorter courses than historically prescribed for many infections. Uncomplicated UTI (cystitis) requires only 3-5 days of therapy. Community-acquired pneumonia in patients achieving clinical stability can be treated for 5 days (rather than traditional 7-10 days). Uncomplicated skin and soft tissue infections require 5-7 days. Intra-abdominal infections with adequate source control require 4 days. Shorter courses reduce antibiotic exposure, costs, and complications without compromising outcomes. In contrast, certain infections require prolonged therapy: native valve endocarditis (4-6 weeks), osteomyelitis (6 weeks), and prosthetic joint infections (variable, often with suppressive therapy). Duration is often extended in immunocompromised patients with slow clinical response.

<image> Panel A: Decision algorithm for empiric antibiotic selection showing the clinical factors to assess: infection syndrome identification, likely pathogens, local resistance patterns (antibiogram), patient factors (allergies, renal/hepatic function, immunocompromise), and drug factors (penetration, interactions, toxicity).

Panel B: Empiric therapy summary table showing first-line recommendations for common infections: CAP (outpatient and inpatient), UTI, cellulitis (MSSA vs MRSA), intra-abdominal, and meningitis, with alternatives for penicillin-allergic patients.

Panel C: De-escalation flowchart showing the process from broad-spectrum empiric therapy through culture results and susceptibility testing to narrowed directed therapy, with criteria for IV-to-oral conversion.

Panel D: Duration of therapy comparison showing traditional versus evidence-based shorter durations for uncomplicated UTI, CAP, cellulitis, and intra-abdominal infections, with rationale for shortened courses. </image>

IX. Antimicrobial Stewardship

Antimicrobial stewardship encompasses coordinated interventions to optimize antimicrobial use, improve patient outcomes, reduce antimicrobial resistance, and decrease healthcare costs. The core elements defined by the Centers for Disease Control and Prevention include hospital leadership commitment, accountability (designating a physician leader), pharmacy expertise (designating a pharmacist leader), implementing interventions to improve prescribing, tracking antibiotic prescribing and resistance patterns, reporting information to prescribers, and educating clinicians. Stewardship programs have demonstrated reductions in antimicrobial use, C. difficile infection rates, resistance emergence, and drug costs without negatively affecting clinical outcomes.

The foundational principle of stewardship is prescribing the right drug at the right dose for the right duration for each patient. This encompasses selecting the most narrow-spectrum agent effective for the pathogen, ensuring adequate dosing based on pharmacokinetic/pharmacodynamic principles and patient factors, using the appropriate route (oral when appropriate), and limiting duration to the shortest effective course. De-escalation from broad-spectrum empiric therapy based on culture results is a cornerstone strategy. Avoiding unnecessary antimicrobial use for non-bacterial conditions (viral upper respiratory infections, asymptomatic bacteriuria in most patients) is equally important.

Stewardship programs employ various intervention strategies. Prospective audit and feedback involves stewardship team review of antimicrobial prescriptions with recommendations provided to prescribers; this approach maintains prescriber autonomy while providing education and expertise. Formulary restriction and preauthorization require approval for selected high-value or high-risk antimicrobials; this can rapidly influence prescribing but may be perceived as restrictive. Antibiotic time-outs (scheduled reassessment of antibiotic necessity at 48-72 hours) prompt de-escalation decisions. Clinical decision support through electronic health record alerts provides real-time guidance on dosing, drug interactions, and guideline-concordant therapy. Development and implementation of institution-specific treatment guidelines, informed by local antibiograms and evidence-based recommendations, standardizes care and facilitates appropriate empiric therapy selection.

Measurement and feedback are essential for stewardship program effectiveness. Antibiotic use metrics include days of therapy (DOT) per 1000 patient-days and defined daily doses (DDD), tracked overall and for specific agents or units. Outcome metrics include C. difficile infection rates, rates of specific resistant organisms (MRSA, VRE, ESBL, CRE), and clinical outcomes (mortality, length of stay, readmission rates). Process metrics include guideline adherence, appropriate empiric therapy rates, de-escalation rates, and IV-to-oral conversion rates. Regular reporting of these metrics to prescribers, unit leadership, and hospital administration maintains engagement and drives improvement. Benchmark comparisons with peer institutions through the CDC National Healthcare Safety Network and other databases contextualize performance.

<image> Panel A: Illustration of the CDC core elements of hospital antibiotic stewardship showing the interconnected components: leadership commitment, accountability (physician leader), pharmacy expertise, action (interventions), tracking (measuring prescribing and resistance), reporting (providing feedback), and education.

Panel B: Comparison of stewardship intervention strategies showing prospective audit with feedback (pharmacist reviewing prescription, making recommendation to physician), preauthorization (physician calling for approval), and clinical decision support (EHR alert suggesting alternative).

Panel C: Antibiotic use metrics dashboard showing DOT/1000 patient-days trends over time, with breakdown by antibiotic class and comparison to benchmark, demonstrating reduction following stewardship implementation.

Panel D: Outcomes pyramid showing the hierarchy of stewardship goals: base (appropriate antibiotic use), middle tier (reduced C. difficile, reduced resistance), apex (improved clinical outcomes, reduced costs), with measurement approaches for each level. </image>

X. Special Considerations

Antimicrobial selection during pregnancy requires careful consideration of fetal safety alongside maternal benefit. Beta-lactams (penicillins, cephalosporins) have extensive safety data and are first-line for most infections in pregnancy. Azithromycin is considered safe. Nitrofurantoin is appropriate for UTI except near term (when it may cause hemolysis in G6PD-deficient neonates). Metronidazole is safe in the second and third trimesters (first-trimester data are limited but reassuring). Drugs with documented fetal risk include tetracyclines (teeth and bone abnormalities), fluoroquinolones (potential cartilage toxicity, though human data are reassuring for short courses), aminoglycosides (ototoxicity), and trimethoprim (folate antagonism, especially first trimester). Sulfonamides should be avoided near term due to kernicterus risk. Consultation with maternal-fetal medicine specialists may be valuable for complex infections requiring higher-risk agents.

Renal impairment affects the pharmacokinetics of many antimicrobials, requiring dose adjustment to prevent accumulation and toxicity while maintaining efficacy. Antibiotics eliminated primarily by the kidneys include aminoglycosides, vancomycin, most beta-lactams, fluoroquinolones, and trimethoprim-sulfamethoxazole. Dose reduction (lower dose with same interval) or interval extension (same dose with longer interval) are strategies employed based on creatinine clearance. Drugs that do not require renal adjustment include azithromycin, doxycycline, clindamycin, rifampin, and metronidazole, which undergo primarily hepatic metabolism or biliary excretion. Therapeutic drug monitoring for aminoglycosides and vancomycin is especially important in renal impairment to guide dosing adjustments.

Drug interactions with antimicrobials are common and clinically important. Rifampin is an extremely potent CYP450 inducer, reducing concentrations of warfarin, oral contraceptives, HIV protease inhibitors, cyclosporine, and many other drugs. Macrolides (especially erythromycin and clarithromycin) and azole antifungals are CYP3A4 inhibitors, increasing levels of statins (rhabdomyolysis risk), calcineurin inhibitors, and other substrates. Fluoroquinolones and tetracyclines are chelated by divalent and trivalent cations (calcium, magnesium, aluminum, iron), requiring separation from antacids, dairy products, and mineral supplements. Metronidazole causes a disulfiram-like reaction with alcohol. Linezolid as a weak MAO inhibitor can cause serotonin syndrome with serotonergic drugs.

Antibiotic allergy is commonly reported but often not a true IgE-mediated hypersensitivity. Detailed allergy history should characterize the reaction (timing, symptoms, prior tolerance) to distinguish true allergy from intolerance or non-immune reactions. Penicillin allergy is reported in approximately 10 percent of patients, but fewer than 1 percent of the population has true IgE-mediated allergy, and over 80 percent of those with documented allergy lose their sensitivity over 10 years. Penicillin skin testing can safely identify patients who can receive penicillins. Cross-reactivity between penicillins and cephalosporins was historically overstated (based on contamination of early cephalosporin preparations); risk is primarily with cephalosporins sharing similar R1 side chains. Aztreonam does not cross-react with penicillins except ceftazidime (same side chain). Carbapenems have low cross-reactivity (approximately 1 percent) with penicillins and can generally be used after non-severe penicillin reactions. Addressing antibiotic allergy labels through appropriate evaluation enables optimal antibiotic selection.

<image> Panel A: Antibiotic safety chart for pregnancy showing safe agents (beta-lactams, azithromycin, nitrofurantoin, metronidazole) in green, agents with potential risk (fluoroquinolones, TMP-SMX in first trimester) in yellow, and contraindicated agents (tetracyclines, aminoglycosides) in red, with specific risks noted.

Panel B: Renal dosing adjustment diagram showing how creatinine clearance categories determine dose and interval adjustments for renally eliminated antibiotics, with examples for gentamicin, vancomycin, and levofloxacin.

Panel C: Drug interaction alert showing major interactions: rifampin (CYP inducer, reducing levels of many drugs), macrolides (CYP inhibitor, increasing statin toxicity), fluoroquinolones (chelation with cations), and linezolid (MAO inhibitor, serotonin syndrome).

Panel D: Penicillin allergy evaluation flowchart showing detailed history assessment, skin testing for appropriate candidates, and guidance for alternative antibiotic selection based on reaction type (IgE-mediated versus intolerance), with cross-reactivity information for cephalosporins, carbapenems, and aztreonam. </image>

Summary

• Beta-lactams inhibit cell wall synthesis by binding PBPs; exhibit time-dependent killing; classes include penicillins, cephalosporins (five generations), carbapenems, and monobactams; resistance via beta-lactamases (ESBLs, carbapenemases) and altered PBPs (MRSA)
• Vancomycin binds D-Ala-D-Ala, inhibiting cell wall synthesis; covers MRSA and C. difficile (oral); monitor levels; VRE resistance via D-Ala-D-Lac
• Daptomycin causes membrane depolarization; active against MRSA and VRE; cannot use for pneumonia (surfactant inactivation)
• Aminoglycosides bind 30S subunit causing misreading; concentration-dependent bactericidal; nephrotoxicity and ototoxicity; synergy with cell wall agents for enterococcal endocarditis
• Macrolides and clindamycin bind 50S subunit; macrolides cover atypicals; clindamycin for anaerobes but C. difficile risk; D-test for inducible resistance
• Linezolid is an oxazolidinone binding 50S; covers MRSA and VRE; myelosuppression with prolonged use; serotonin syndrome risk with SSRIs
• Fluoroquinolones inhibit DNA gyrase/topoisomerase IV; concentration-dependent; black box warnings for tendon rupture, QT prolongation, aortic effects
• Metronidazole generates cytotoxic intermediates under anaerobic conditions; covers anaerobes and protozoa; disulfiram reaction with alcohol
• TMP-SMX inhibits folate synthesis sequentially; covers MRSA, UTI pathogens, PCP; sulfa allergy and hyperkalemia risks
• Resistance mechanisms: enzymatic inactivation (beta-lactamases), target modification (altered PBPs, ribosomal methylation), efflux, decreased permeability
• Stewardship principles: right drug, dose, duration; de-escalation based on culture results; avoid unnecessary use; measure and feedback metrics

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown